{"id":5789,"date":"2023-05-09T14:01:18","date_gmt":"2023-05-09T12:01:18","guid":{"rendered":"https:\/\/staybletherapeutics.com\/sv\/cision-feed\/stayble-therapeutics-publicerar-arsredovisningen-for-2022\/"},"modified":"2023-05-09T14:01:18","modified_gmt":"2023-05-09T12:01:18","slug":"stayble-therapeutics-publicerar-arsredovisningen-for-2022","status":"publish","type":"cision-feed","link":"https:\/\/staybletherapeutics.com\/sv\/cision-feed\/stayble-therapeutics-publicerar-arsredovisningen-for-2022\/","title":{"rendered":"Stayble Therapeutics publicerar \u00e5rsredovisningen f\u00f6r 2022"},"content":{"rendered":"

Staybles \u00e5rsredovisning f\u00f6r 2022 finns nu tillg\u00e4nglig p\u00e5 bolagets hemsida (<\/span>https:\/\/staybletherapeutics.com\/sv\/investerare\/finansiella-rapporter\/<\/u><\/span><\/a>) och kan \u00e4ven distribueras i tryckt format till aktie\u00e4gare som s\u00e5 \u00f6nskar. <\/span><\/p>\n

 <\/span><\/p>\n

F\u00f6r mer information<\/span><\/h2>\n

Andreas Gerward, VD Stayble Therapeutics AB<\/span><\/p>\n

E-post: andreas.gerward@stayble.se <\/span><\/p>\n

Telefon: +46 730 808<\/span> <\/span>397<\/span><\/p>\n

 <\/span><\/p>\n

Om Stayble Therapeutics AB<\/span><\/h2>\n

Stayble \u00e4r ett kliniskt l\u00e4kemedelsbolag som utvecklar injektionsbehandlingen STA363 mot degenerativ disksjukdom (DDD) och kroniskt diskbr\u00e5ck (LDH). Staybles vision \u00e4r att kunna erbjuda patienter en enkel och effektiv behandling som angriper den underliggande orsaken patientens kroniska sm\u00e4rta och ger varaktig sm\u00e4rtlindring och \u00f6kad fysisk funktion. Behandlingen riktar sig till patienter som inte blir hj\u00e4lpta av sjukgymnastik och sm\u00e4rtstillande preparat och \u00e4r en singelinjektion som ber\u00e4knas kvarst\u00e5 hela livet och kr\u00e4ver minimal rehabilitering. Bolagets har nu fokus p\u00e5 den fortsatta kliniska utvecklingen och genomf\u00f6r just nu en klinisk fas 2b-studie inom DDD och en fas 1b-studie inom LDH. <\/span><\/p>\n

 <\/span><\/p>\n

Bolagets Certified Adviser \u00e4r Svensk Kapitalmarknadsgranskning AB.<\/span><\/p>\n

 <\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Stayble Therapeutics AB (\u201dStayble\u201d eller \u201dBolaget\u201d) publicerar idag \u00e5rsredovisningen f\u00f6r 2022. \u00c5rsredovisningen finns tillg\u00e4nglig p\u00e5 bolagets hemsida (https:\/\/staybletherapeutics.com\/sv\/investerare\/finansiella-rapporter\/) och bifogad i detta utskick.<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed\/5789"}],"collection":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed"}],"about":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/types\/cision-feed"}],"replies":[{"embeddable":true,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/comments?post=5789"}],"version-history":[{"count":0,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed\/5789\/revisions"}],"wp:attachment":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/media?parent=5789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}